SCHEMBL3492865

SCHEMBL3492865

NNC(=O)c1cnc2occ(-c3ccccc3Cl)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.40
HDAC6 Q9UBN7 3/20 0.38
MAP4K4 O95819 1/20 0.38
HDAC1 Q13547 4/20 0.37
EGLN1 Q9GZT9 2/20 0.36
EGLN3 Q9H6Z9 2/20 0.36
HTR5A P47898 1/20 0.36
ALDH1A1 P00352 2/20 0.35
NPC1 O15118 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
CTSA P10619 1/20 0.35
HDAC3 O15379 2/20 0.35
HDAC2 Q92769 2/20 0.35
DEGS1 O15121 1/20 0.35
HDAC8 Q9BY41 1/20 0.34
PRKDC P78527 1/20 0.34
ATR Q13535 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3491101 0.83 GPBAR1 (0.42) EGLN1EGLN3ALDH1A1NPC1HPGD
SCHEMBL3492239 0.79 HDAC6 (0.44) HDAC6HDAC1ALDH1A1HDAC3HDAC2
SCHEMBL3490770 0.75 GSK3B (0.37) HDAC6HDAC1ALDH1A1CYP1A2CYP2C19
SCHEMBL3491971 0.67 NPC1 (0.40) ALDH1A1NPC1HPGD
SCHEMBL13977996 0.65 ALDH1A1 (0.54) ALDH1A1NPC1
SCHEMBL3579289 0.65 CAMKK2 (0.45) ALDH1A1NPC1FLT1
SCHEMBL3492780 0.64 NQO2 (0.49) ALDH1A1NPC1HPGD
SCHEMBL218035 0.64 KDM4E (0.49) HDAC6ALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL30962742 0.64 IKBKB (0.45) MAP4K4HDAC1EGLN1HTR5AALDH1A1
SCHEMBL31295356 0.64 NAPRT (0.60) ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492378-B2 GSK-3β inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-23 US disclosed
US-20100069381-A1 GSK-3BETAINHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069381-A1 GSK-3BETAINHIBITOR GSK3B, GSK3A, GSKIP CNR1 4491/4885HDAC6 267/4885MAP4K4 1206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.